A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

A novel bispecific antibody for EGFR-directed blockade of the PD-1/PD-L1 immune checkpoint

PD-L1-blocking antibodies produce significant clinical benefit in selected cancer patients by reactivating functionally-impaired antigen-experienced anticancer T cells. However, the efficacy of current PD-L1-blocking antibodies is potentially reduced by ‘on-target/off-tumor’ binding to PD-L1 widely...

Full description

Bibliographic Details
Main Authors: Iris Koopmans, Djoke Hendriks, Douwe F. Samplonius, Robert J. van Ginkel, Sandra Heskamp, Peter J. Wierstra, Edwin Bremer, Wijnand Helfrich
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
bispecific antibody
egfr
immunotherapy
pd-l1
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1466016

Internet

http://dx.doi.org/10.1080/2162402X.2018.1466016

Similar Items